Given the high prevalence of hypertension, with or without coexisting diabetes, and its central role in cardiovascular morbidity, it is essential to evaluate whether SGLT-2 inhibitors provide comparable cardiovascular benefits across these subgroups. This evidence concerns the gene SLC5A2 and diabetes mellitus.